News

The once-daily, steroid-free topical is now approved to treat plaque psoriasis of the scalp and body in patients aged 12 years and older.

“These findings provide evidence that social media may be contributing to the development of depressive symptoms,” said Jason M. Nagata, MD, MSc.

Victor Carrion, MD, emphasizes how pediatricians can monitor and support mental health in youth while navigating limited access to specialized care.

The expanded indication follows original approval in August 2018 for use in previously-treated patients 12 years and older.

These findings come as many health care professionals still report limited confidence and inconsistent practices regarding RSV immunization discussions.

Most videos on TikTok regarding hormonal contraception were misleading, according to a study presented at the 2025 ACOG Annual Clinical and Scientific Meeting.

Our editor-in-chief Tina Tan, MD, reacts to a new FDA COVID-19 framework that will limit eligibility for seasonal vaccination in pediatrics.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Albuterol-budesonide (Airsupra; AstraZeneca) resulted in a 47% reduction in severe exacerbations in mild asthma vs albuterol alone.

Severe RSV disease in 2022–2023 was most likely to occur in infants under 6 months and older children with pulmonary or neurologic conditions.

Colleen Sloan, PA-C, RDN, highlights what she is seeing in practice related to screen time, devices, and social media and impacts on nutrition.

Delandistrogene moxeparvovec-rokl (ELEVIDYS) showed significant motor function improvements in 8- to 9-year-old Duchenne muscular dystrophy patients in part 2 of the phase 3 EMBARK study.

Music therapist Jenna Marcovitz discusses the role of pediatricians in making timely referrals to music therapy to support whole-child health.

Somapacitan was non-inferior and had a similar safety profile and clinical outcomes compared to once-daily somatropin in improving yearly growth rates.

The nearly 4000 cases in 2023 were the highest number reported in over 30 years, the Task Force stated.

Safety, phosphate level gains, and immunogenicity data offer encouraging signals in the pivotal trial.

The federal agency provided BioCryst Pharmaceuticals a target action date of September 12, 2025 for potential approval of berotralstat (ORLADEYO).

The administration has set a goal date of October 31 to complete a safety review, public comment period, and to take "appropriate action" in efforts to remove products from the market.

According to the agency, it is seeking public input to "determine whether existing nutrient requirements should be revised based on latest scientific data."

This FDA decision will help to improve clarity and diagnostic accuracy of echocardiograms in pediatric patients, according to GE HealthCare.

Maternal avocado consumption during pregnancy was linked to significantly lower odds of infant food allergy at 12 months.

The in vivo hematopoietic stem cell-directed therapy received rare pediatric disease and orphan drug designations earlier this year.

"Early identification of high-risk neonates may enable targeted strategies to support respiratory health," stated the study investigators.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

In this video interview, Jenna Marcovitz, MA, MT-BC, CCLS, RMT, provides insight to music therapy and how it can benefit a wide range of pediatric patients.

"These findings support Advisory Committee on Immunization Practices’ recommendations for maternal vaccination or nirsevimab to protect against severe RSV disease in infants," wrote the MMWR study investigators.

Subgroup data show crinecerfont helps children with CAH reduce steroid use while maintaining or improving androstenedione levels across diverse patient groups.

Zhang Meng shares how advancements in technology have helped prevent early cavities in childhood, and how to counsel your young patients on good oral health.